title: Long-term morphine treatment enhances proteasome-dependent degradation of G beta in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylate cyclase sensitization.
abstract: The initial aim of this study was to identify protein changes associated with long-term morphine treatment in a recombinant human neuroblastoma SH-SY5Y clone (sc2) stably overexpressing the human mu-opioid (MOP) receptor. In MOP receptor-overexpressing sc2 cells, short-term morphine exposure was found to be much more potent and efficacious in inhibiting forskolin-elicited production of cAMP, and long-term morphine exposure was shown to induce a substantially higher degree of opiate dependence, as reflected by adenylate cyclase sensitization, than it did in wild-type neuroblastoma cells. Differential proteomic analysis of detergent-resistant membrane rafts isolated from untreated and chronically morphine-treated sc2 cells revealed long-term morphine exposure to have reliably induced a 30 to 40% decrease in the abundance of five proteins, subsequently identified by mass spectrometry as G protein subunits alphai(2), alphai(3), beta(1), and beta(2), and prohibitin. Quantitative Western blot analyses of whole-cell extracts showed that long-term morphine treatment-induced down-regulation of Gbeta but not of the other proteins is highly correlated (r(2) = 0.96) with sensitization of adenylate cyclase. Down-regulation of Gbeta and adenylate cyclase sensitization elicited by long-term morphine treatment were suppressed in the presence of carbobenzoxy-l-leucyl-l-leucyl-l-norvalinal (MG-115) or lactacystin. Thus, sustained activation of the MOP receptor by morphine in sc2 cells seems to promote proteasomal degradation of Gbeta to sensitize adenylate cyclase. Together, our data suggest that the long-term administration of opiates may elicit dependence by altering the neuronal balance of heterotrimeric G proteins and adenylate cyclases, with the ubiquitin-proteasome pathway playing a pivotal role.
authors.affiliation: IPBS-CNRS UMR5089, 205 route de Narbonne, 31077 Toulouse cédex 04, France.
authors.forename: Lionel
authors.initials: L
authors.lastname: Moulédous
authors.forename: Jérémie
authors.initials: J
authors.lastname: Neasta
authors.forename: Sandrine
authors.initials: S
authors.lastname: Uttenweiler-Joseph
authors.forename: Alexandre
authors.initials: A
authors.lastname: Stella
authors.forename: Mariette
authors.initials: M
authors.lastname: Matondo
authors.forename: Maïthé
authors.initials: M
authors.lastname: Corbani
authors.forename: Bernard
authors.initials: B
authors.lastname: Monsarrat
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Meunier
mesh_terms: D000262:Adenylyl Cyclases / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D044387:GTP-Binding Protein beta Subunits / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009020:Morphine / Q000008:administration & dosage*; D009447:Neuroblastoma / Q000235:genetics / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex / Q000235:genetics / Q000378:metabolism*; D013997:Time Factors
chemical_list: D044387:GTP-Binding Protein beta Subunits; D009020:Morphine; D046988:Proteasome Endopeptidase Complex; D000262:Adenylyl Cyclases